Specialised ethical guidance is needed to help clincian-researchers manage the unique ethical complexities of research in deceased donation and transplantation during the end of life period.

While corticosteroids are a key component of immunosuppressive treatment after heart transplantation, several adverse effects are associated with long-term use and may compromise post-transplant outcome. To address the lack of consensus on corticosteroid withdrawal, this review evaluates different approaches in relation to clinical outcomes.

In this systematic review we firstly reviewed the reported studies and discussed the use of EBV-CTLs in the treatment of refractory PTLD of SOT recipients. We found that EBV-CTL therapy was reliable and effective.

This study presents two prediction models for graft and patient survival using granular data. Even in the worst risk-prediction scenario, KT seems to provide better patient survival expectancy as compared with remaining on the waiting list but with a high mortality risk if this high-risk kidney transplantation is undertaken.

A total of 852 KT recipients aged ≥65 years (575 from DBD and 277 from cDCD) were included in the analysis. The 3-year patient and death-censored graft survival rates were similar between DBD and cDCD-KT (78.8% vs. 76.4% and 90.3% vs. 86.6%, respectively). Cardiovascular disease and DGF were independent risk factors for patient death. The type of donation (cDCD vs. DBD) did not impact in patient survival/graft loss.

Pre-liver transplant (LT) chronic kidney disease (CKD) has emerged as a leading cause of post-operative morbidity. We aimed to report the prevalence, associated risk factors and clinical outcomes in patients with pre-LT CKD

Cumulative incidence of chronic kidney disease (CKD) increased from 31.44% at 1-year to 43.52% at 5-years after LT. Age, female sex, diabetes, and peri-operative acute kidney injury were significant risk factors for CKD. Importantly, stage 4–5 CKD was associated with significantly lower overall survival (HR 3.23, 95% CI 1.74–5.98, P < 0.01).

Full-left-full-right split liver transplantation is associated with increased risk for vascular and biliary complications. However, survival appears acceptable and justifies transplant benefit in selected patients.

Graft Infiltrating Lymphocytes (GILs) change their immunological behavior depending on time after transplantation. While 120 h GILs show very strong alloreactivity, 72 h GILs show very weak alloreactivity and do not reject allograft by themselves.

In this study, we found candidate's Willingness to accept organs from HCV+ donors rose significantly with DAA availability, benefitting kidney and liver candidates with increased deceased-donor organ transplantation rates and shortened kidney candidates wait time.

This manuscript resumes a Brazilian and Colombian experience with fifteen uterus retrieval from deceased donors, it explains the surgical technique evolution and compares it with other experiences around the world in the same field.

The patient satisfaction with outpatient care is high after heart transplantation in Germany. The quality of life of patients after pediatric heart transplantation is comparable with a standardized German population. Patients after adult heart transplantation show reduced physical and emotional functioning.

Exercise capacity, muscle strength and physical activity of patients after heart transplantation significantly improve during the first year after surgery. However, results remain below levels of age-and gender matched healthy subjects. Promoting cardiac rehabilitation and improving physical activity in this patient group are essential.

Although Sweden had a controversial approach to the COVID pandemic, this retrospective study of lung transplant recipients indicates a good general survival in this vulnerable group of patients.

Lung transplantation from uncontrolled and controlled donors after circulatory death offers similar outcomes to brain death donors in terms of early and mid-term results. Overall survival and CLAD-free survival at 1 and 3 years are comparable between the three types of donors.

We assessed the prevalence and prognostic implications of post CLAD onset phenotype transitions in a large cohort of lung transplant recipients. We have shown that CLAD patients who later changed their phenotype due to the appearance of RAS-like opacities had a significantly worse outcome. Potential event leading to these changes also described.

This single-center study represents the first large-scale analysis of long-term outcomes of alemtuzumab induction therapy, followed by a low-dose dual drug maintenance immunosuppression after lung transplantation. The results presented in the manuscript show excellent long-term outcomes, with low rates of severe infections and malignancies.

Although informing end-stage kidney disease patients about kidney transplantation options increased the likelihood of choosing these options, information provided by for-profit centers were less effective than those provided by nonprofit centers. Developing standardized guidelines for providing consistent transplantation information is critical.

A retrospective study with all Dutch pregnant kidney transplant recipients in 1986–2017, where maternal and foetal pregnancy outcomes were compared between patients using a CNI immunosuppressive regimen and patients, not using CNIs.

A BK polyomavirus (BKPyV) screening protocol was implemented across 11 transplant centers. Adherence to the screening protocol was low, but was positively correlated with both an increase in the detection of BKPyV infection as well as an unexpected increase in the diagnosis of BKPyV associated nephropathy.

In a cohort of 214 kidney transplant recipients hospitalized with UTI, a short course antibiotic treatment (6–10 days) was as effective as longer course (11–21 days) with regards to re-hospitalization, relapse UTI, and mortality.

Living kidney donors may be pre-symptomatic but at risk for the genetic disorder affecting their related transplant recipient. We report an optimized workflow to assess genetic disease in transplant recipients, then using that information to perform focused screening of the related living donor, thus improving their informed choice and safety.

ABO-incompatible kidney transplantation has better patient survival than matched deceased donor transplantation, however with inferior graft survival as compared to matched living donor ABO-compatible transplantation. Rejection rates differ according to induction therapy, and graft survival differs according to blood group titers.

Valganciclovir is the best efficacy and safety in long-term CMV prophylaxis in kidney transplant recipients regarding in high-risk group, while ganciclovir is the second rank. For valacyclovir is an alternative in a valgaciclovir-limited area when regardless of donor/recipients CMV serologies.

Outcome of small-donor kidney transplantation in children was excellent, especially in case of very small donor or recipient size. It was not impaired by high perioperative complication rates, low early graft function, or single grafts and therefore should be pursued in specialized centres.

Increasing numbers of elderly (≥65 years) patients are listed for kidney transplantation. In elderly recipients the patient survival benefits of a living donor kidney are limited, but there is decreased death-censored graft loss for these recipients. Nevertheless, graft survival for recipients with a deceased donor remains satisfactory.

In this nationwide prospective multicenter cohort, 10% of transplants showed a poor first-year outcome. Presence of pre-transplant DSA per se did not affect first year outcomes. However, occurrence of first year rejection in DSA-positive transplants was, in contrast to those without rejection, associated with a poor allograft survival.

Preemptive KT declined over successive years in Korea. The proportion of diabetes increased and that of glomerulonephritis decreased among preemptive KT. Short period of dialysis less than 6 months does not affect graft survival compared with preemptive KT; however, longer dialysis decreases graft survival.

Living kidney donation is underutilized in the United States particularly in minorities and technology-based interventions (TBI) such as mobile applications and interactive websites may help reduce this disparity. In our scoping review, we determined that TBI may serve as a way to connect potential donors and transplant candidates.

Recipient smoking status before kidney transplantation is dose-dependently associated with impaired kidney transplant survival. Considering the dose-dependent effects of smoking, a smoking cessation program may be necessary at the start of managing chronic kidney disease.

PAK recipients are in a unique situation as they are exposed to different HLA antigens from the two different donors.

First-in-man trial of adoptive cell therapy with autologous regulatory T cells in clinical intraportal allogenic pancreatic islet transplantation.

Chronic kidney disease (CKD) is common following liver transplantation. We investigated risk factors, and impact of CKD on cardiovascular disease (CVD), graft/patient survival. A higher tacrolimus concentration to dose ratio was protective for CKD (OR 0.69). CKD led to increased post-transplant CVD (26% vs. 16%), and reduced graft/patient survival.

Adjusting for obesity class, black liver transplant recipients in the United States had a 20% lower patient survival and 23% lower graft survival compared to non-black recipients. Thus, obesity seems to compound other known factors associated with poor outcomes after liver transplantation.

We aimed to investigate the role of percutaneous biliary interventions in the management of biliary complicaitons in donors after living donor liver transplantation.

With the introduction of MELD-Na-based allocation in the United States, waitlist outcomes (waitlist mortality and transplant probability) have improved in patients with extreme hyponatremia (≤120 mEq/l). However, these patients continue to have inferior short-term post-LT survival outcomes.

In a Swedish single-center study, the RETREAT score performs well in predicting the recurrence of hepatocellular carcinoma after liver transplantation. These data could be used for tailoring surveillance and immunosuppression treatments.

We constructed a risk-scoring tool informing decision making upon allocating human liver grafts to patients hepatocellular carcinoma.

Intraoperative blood salvage (IBS) reduces the use of allogeneic blood transfusion. However, safety of IBS during liver transplantation (LT) for hepatocellular carcinoma (HCC) is questioned due to fear for dissemination of circulating malignant cells. Based in present propensity score matched analysis, IBS during LT did not increase the risk for HCC recurrence.